Developing novel agents to prevent tumour recurrence in glioblastoma

开发预防胶质母细胞瘤肿瘤复发的新药

• 批准号: nhmrc : 2003150
• 金额: $ 108.96万
• 依托单位国家: 澳大利亚
• 项目类别: Ideas Grants
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2024-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/developing-novel-agents-recurrence-glioblastoma/1780074
• 关键词: Developing; novel; agents; prevent; tumour

Glioblastoma is a form of brain cancer that is currently incurable. We have discovered that switching-off an enzyme called KDM4 (using 'KDM4 inhibitors') improves chemotherapy outcomes with new drugs also discovered in our laboratory. This project will examine a novel drug combination treatment for glioblastoma patients and generate evidence for initiation of clinical trials. This could initiate a novel therapy that could significantly extend patients' lives.

胶质母细胞瘤是一种目前无法治愈的脑癌。我们发现，在我们实验室发现的新药中，关闭一种名为KDM4的酶(使用KDM4抑制剂)可以改善化疗效果。该项目将研究一种针对胶质母细胞瘤患者的新型药物联合治疗方法，并为临床试验的启动提供证据。这可能会启动一种新的治疗方法，可以显著延长患者的生命。